Joleen M. Hubbard, MD

home / authors / joleen-m-hubbard-md

Articles

Challenges With Molecular Testing in Metastatic Colorectal Cancer

Kristen Ciombor, MD, MSCI;Joleen M. Hubbard, MD;Joel R. Hecht, MD;Pashtoon M. Kasi, MD, MS;Kanwal Raghav, MD

February 16th 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

Circulating Tumor DNA to Guide Treatment Selection for mCRC

Kristen Ciombor, MD, MSCI;Joleen M. Hubbard, MD;Joel R. Hecht, MD;Pashtoon M. Kasi, MD, MS;Kanwal Raghav, MD

February 16th 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC

Kristen Ciombor, MD, MSCI;Joleen M. Hubbard, MD;Joel R. Hecht, MD;Pashtoon M. Kasi, MD, MS;Kanwal Raghav, MD

February 9th 2023

Shared insight on the value tissue and circulating tumor DNA respectively provide in molecular testing for patients with metastatic colorectal cancer.

Overview of Molecular Testing in Metastatic Colorectal Cancer (mCRC)

Kristen Ciombor, MD, MSCI;Joleen M. Hubbard, MD;Pashtoon M. Kasi, MBBS, MD, MS;Kanwal Raghav, MD;Joel R. Hecht, MD

February 9th 2023

Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.

Dr. Hubbard on the Use of the PolyPEPI1018 Vaccine Plus Chemotherapy in Metastatic CRC

Joleen M. Hubbard, MD

January 27th 2023

Joleen M. Hubbard, MD, discusses key survival data from the phase 1b study of the PolyPEPI1018 vaccine and the impact of these findings on continued investigations of this vaccine in metastatic colorectal cancer.

Tucatinib plus trastuzumab in patients (pts) with HER2-Positive Metastatic Colorectal Cancer (mCRC): Patient Reported Outcomes from MOUNTAINEER

Joleen M. Hubbard, MD

October 5th 2022

Dr Hubbard reviews patient reported outcomes from the MOUNTAINEER trial, which evaluated the combination of tucatinib plus trastuzumab in patients with HER2-positive metastatic colorectal cancer.

<1 2